Answers are grounded in this paper and cite their sources.
Our results suggest potentially broad therapeutic use of BET bromodomain inhibitors for treating genetically diverse glioblastoma tumors.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: